Polymorphisms in the Serotonin Transporter Protein (SERT) Gene in Patients With Pulmonary Arterial Hypertension;Polimorfismos en el gen de la proteína transportadora de serotonina (SERT) en pacientes con hipertensión arterial pulmonar

Archivos de Bronconeumologia

Volumn 48, Issue 3, 2012, Pages 77-80

  Baloira, Adolfo ^a   Núñez, Marta ^a   Cifrian, José ^b   Vilariño, Carlos ^c   Ojeda, María ^d   Valverde, Diana ^d  

^a HOSPITAL MONTECELO   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d UNIVERSITY OF VIGO   (Spain)

Author keywords

Polymorphisms; Pulmonary arterial hypertension; Serotonin; Serotonin transporter protein (SERT)

Indexed keywords

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; ELECTROPHORESIS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; HUMAN; IDIOPATHIC DISEASE; LUNG EMBOLISM; LUNG PRESSURE; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PULMONARY HYPERTENSION; SEROTONIN TRANSPORTER GENE; BLOOD SAMPLING; DISEASE SEVERITY; DNA EXTRACTION; ESSENTIAL HYPERTENSION; GENE FUNCTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MIDDLE AGED; PULMONARY ARTERY CATHETERIZATION; SERT GENE; THROMBOEMBOLISM;

ADULT; AGED; ALLELES; CONNECTIVE TISSUE DISEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HEART DEFECTS, CONGENITAL; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMBOLISM; SAMPLING STUDIES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPAIN;

SEROTONIN TRANSPORTER;

EID: 84857193974     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2011.10.008     Document Type: Article

References (18)

1. Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips J.A., Loyd J.E., et al. Heterozygous germ-line mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000, 26:81-84.
2. Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67:737-744.
3. Lee S.L., Wang W.W., Moore B.J., Fanburg B.L. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Cir Res 1991, 68:1362-1368.
4. Herve P., Launay J.M., Scrobohaci M.L., Brenot F., Simonneau G., Petitpretz P., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995, 99:249-254.
5. Eddahibi S., Raffestin B., HamonM, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?. J Lab Clin Med 2002, 139:194-201.
6. Eddahibi S., Chaouat A., Morrell N., Fadel E., Fuhrman C., Bugnet A., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003, 108:1839-1844.
7. Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001, 108:1141-1150.
8. Galié N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009, 30:2493-2537.
9. Marcos E., Fadel E., Sanchez O., Humber M., Dartevelle P., Simmoneau G., et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004, 94:1263-1270.
10. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
11. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., et al. Long term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
12. Dempsie Y., MacLean M.R. Pulmonary hypertension: Therapeutic targets within the serotonin system. Br J Pharmacol 2008, 155:455-462.
13. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 335:609-616.
14. Welsh D.J., Harnett M., MacLean M., Peacock A.J. Proliferation and signalling in fibroblasts-role of 5-hydroxytriptamine (2A) receptor and transporter. Am J Respir Crit Care Med 2004, 170:252-259.
15. Launay J.M., Herve P., Peoc'h K., Tournois C., Callebert J., Nebigil C.G., et al. Function of the serotonin 5-hydroxytriptamine 2B receptor in pulmonary hypertension. Nat Med 2002, 8:1129-1135.
16. Willers E.D., Newman J.H., Loyd J.E., Robbins I.M., Wheeler L.A., Prince M.A., et al. Serotonin transporter polymorphisms in familial and idiopathic pulmonary hypertension. Am J Respir Crit Care Med 2006, 173:798-802.
17. Machado R.D., Koehler R., Glissmeyer E., Veal C., Suntharalingam J., Kim M., et al. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 173:793-797.
18. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., et al. Pulmonary arterial hypertension in France. Am J Respir Crit Care Med 2006, 173:1023-1030.